Skip to main content
SpringerLink
Log in
Book cover

Buprenorphine Therapy of Opiate Addiction pp 29–49Cite as

High-Dose Buprenorphine for Treatment of Opioid Dependence

  • Chapter

  • 111 Accesses

Part of the book series: Forensic Science and Medicine ((FSM))

Abstract

Buprenorphine was first approved and marketed as an analgesic. When used for this indication, it is typically administered by injection, and the recommended dose is 0.3 mg every 6 h. Higher doses, such as 0.6 mg every 6 h, may be indicated in cases of severe pain. Thus, the recommended total daily analgesic dose is 1.2–2.4 mg.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35: 501–16.

    Article  PubMed  CAS  Google Scholar 

  2. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science 1980; 207: 657–9.

    Article  PubMed  CAS  Google Scholar 

  3. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43: 72–8.

    Article  PubMed  CAS  Google Scholar 

  4. Kuhlman JJ, Lalani S, Magluilo J, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996; 20: 369–78.

    PubMed  CAS  Google Scholar 

  5. Cowan A, Doxey JC, Harry EJ. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977; 60: 547–54.

    PubMed  CAS  Google Scholar 

  6. Doxey JC, Everitt JE, Frank LW, MacKenzie JE. A comparison of the effects of buprenorphine and morphine on the blood gases of conscious rats. Br J Pharmacol 1982; 75: 118 P.

    Google Scholar 

  7. Dum JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981; 74: 627–33.

    PubMed  CAS  Google Scholar 

  8. Lizasoain I, Leza JC, Lorenzo P. Buprenorphine: bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol 1991; 22: 297–300.

    Article  PubMed  CAS  Google Scholar 

  9. Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, Mendelson JE. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 1999; 39: 619–23.

    Article  PubMed  CAS  Google Scholar 

  10. Schuh KJ, Johanson CE Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend 1999; 56: 55–60.

    Article  PubMed  CAS  Google Scholar 

  11. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; 2: 485–8.

    Article  PubMed  CAS  Google Scholar 

  12. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119: 23–7.

    PubMed  CAS  Google Scholar 

  13. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40: 17–25.

    Article  PubMed  CAS  Google Scholar 

  14. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93: 475–86.

    Article  PubMed  CAS  Google Scholar 

  15. Fudala PJ, Bridge TP, Herbert S, Chiang CN, Leiderman DB A multi-site efficacy evaluation of a buprenorphine/naloxone product for opiate dependence treatment. NIDA Res Monogr 1998; 179: 105.

    Google Scholar 

  16. Compton PA, Wesson DR, Charuvastra VC, Ling W. Buprenorphine as a pharmacotherapy for opiate addiction: what dose provides a therapeutic response? Am J Addict 1996; 5: 220–30.

    Google Scholar 

  17. Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 1991; 17: 119–28.

    Article  PubMed  CAS  Google Scholar 

  18. Reisinger M. Buprenorphine as new treatment for heroin dependence. Drug Alcohol Depend 1985; 16: 257–62.

    Article  PubMed  CAS  Google Scholar 

  19. Seow SS, Quigley AJ, Ilett KF, Dusci LJ, Swensen G, Harrison-Stewart A, Rappeport L. Buprenorphine: a new maintenance opiate? Med J Aust 1986; 144: 407–11.

    PubMed  CAS  Google Scholar 

  20. Bickel WK, Amass L. Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol 1995; 3: 477–89.

    Article  CAS  Google Scholar 

  21. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267: 2750–5.

    Article  PubMed  CAS  Google Scholar 

  22. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nery Ment Dis 1993; 181: 358–64.

    Article  CAS  Google Scholar 

  23. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) 1994; 116: 401–6.

    Article  CAS  Google Scholar 

  24. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151: 1025–30.

    PubMed  CAS  Google Scholar 

  25. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53: 401–7.

    Article  PubMed  CAS  Google Scholar 

  26. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54: 713–20.

    Article  PubMed  CAS  Google Scholar 

  27. Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry 1999; 56: 812–20.

    Article  PubMed  CAS  Google Scholar 

  28. Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94: 1337–47.

    Article  PubMed  CAS  Google Scholar 

  29. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60: 39–50.

    PubMed  CAS  Google Scholar 

  30. Mattick RP, Ali R, White J, O’Brien S, Wolk S, Danz C. A randomised double-blind trial of buprenorphine tablets versus methadone syrup for maintenance therapy: efficacy and cost-effectiveness. NIDA Res Monogr 1999; 180: 77.

    Google Scholar 

  31. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343: 1290–7.

    Article  PubMed  CAS  Google Scholar 

  32. Petitjean S, Stohler R, Deglon J, Livoti S, Waldvogel D, Uehlinger C, Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62: 97–104.

    Article  PubMed  CAS  Google Scholar 

  33. Lange WR, Fudala PJ, Dax EM, Johnson RE. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend 1990; 26: 19–28.

    Article  PubMed  CAS  Google Scholar 

  34. Petry NM, Bickel WK, Piasecki D, Marsch LA, Badger GJ. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000; 9: 265–9.

    Article  PubMed  CAS  Google Scholar 

  35. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998; 93: 1385–92.

    Article  PubMed  CAS  Google Scholar 

  36. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22: 430–4.

    PubMed  CAS  Google Scholar 

  37. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994; 54: 1215–28.

    Article  PubMed  CAS  Google Scholar 

  38. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000; 58: 143–52.

    Article  PubMed  CAS  Google Scholar 

  39. Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl) 1999; 146: 111–8.

    CAS  Google Scholar 

  40. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47: 525–34.

    Article  PubMed  CAS  Google Scholar 

  41. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 1995; 40: 27–35.

    Article  PubMed  CAS  Google Scholar 

  42. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994; 36: 115–21.

    Article  PubMed  CAS  Google Scholar 

  43. Nigam AK, Ray R, Tripathi BM. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat 1993; 10: 391–4.

    Article  PubMed  CAS  Google Scholar 

  44. Parran TV, Adelman CL, Jasinski DR. A buprenorphine stabilization and rapid-taper protocol for the detoxification of opioid-dependent patients. Am J Addict 1994; 3: 306–13.

    Google Scholar 

Download references

Authors
  1. Eric C. Strain
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Legal Medicine, Strasbourg, France

    Pascal Kintz PharmD, PhD (President) (President)

  2. Societé Française de Toxicologie Analytique, France

    Pascal Kintz PharmD, PhD (President) (President)

  3. Department of Pharmacology and Toxicology, University Hospital, France

    Pierre Marquet MD, PhD (Professor of Pharmacology) (Professor of Pharmacology)

  4. Faculty of Medicine, Limoges University, Limoges, France

    Pierre Marquet MD, PhD (Professor of Pharmacology) (Professor of Pharmacology)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Strain, E.C. (2002). High-Dose Buprenorphine for Treatment of Opioid Dependence. In: Kintz, P., Marquet, P. (eds) Buprenorphine Therapy of Opiate Addiction. Forensic Science and Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-282-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-282-1_3

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9713-7

  • Online ISBN: 978-1-59259-282-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation